FDA recommendations on clopidogrel (Plavix) because of decreased response and PPI interactions
Pharmamotion has now a new page containing updates on clopidogrel PPI interactions.
The FDA issued today an early communication about an ongoing safety review of the antiplatelet agent clopidogrel bisulfate (Plavix). The backgroung to this is the recent evidence of:
- A decreased response to clopidogrel in some patients. Since clopidogrel is a prodrug, genetic polymorphisms of cytochrome P450 may determine a lower efficacy.
- Reports that proton pump inhibitors (PPI’s) may inhibit the enzime that produces the active form of the drug.
Here are the recommendations from the FDA until there is further information:
- Healthcare providers should continue to prescribe and patients should continue to take clopidogrel as directed, because clopidogrel has demonstrated benefits in preventing blood clots that could lead to a heart attack or stroke.
- Healthcare providers should re-evaluate the need for starting or continuing treatment with a PPI, including Prilosec OTC, in patients taking clopidogrel.
- Patients taking clopidogrel should consult with their healthcare provider if they are currently taking or considering taking a PPI, including Prilosec OTC.
You may also be interested in:
